Cost-utility analysis in evaluating prophylaxis in haemophilia.
about
Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.Quality of life assessment in clinical practice in haemophilia treatment.Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective.Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.
P2860
Cost-utility analysis in evaluating prophylaxis in haemophilia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cost-utility analysis in evaluating prophylaxis in haemophilia.
@ast
Cost-utility analysis in evaluating prophylaxis in haemophilia.
@en
type
label
Cost-utility analysis in evaluating prophylaxis in haemophilia.
@ast
Cost-utility analysis in evaluating prophylaxis in haemophilia.
@en
prefLabel
Cost-utility analysis in evaluating prophylaxis in haemophilia.
@ast
Cost-utility analysis in evaluating prophylaxis in haemophilia.
@en
P2093
P2860
P1433
P1476
Cost-utility analysis in evaluating prophylaxis in haemophilia.
@en
P2093
P2860
P356
10.1111/J.1355-0691.2004.00879.X
P478
10 Suppl 1
P577
2004-03-01T00:00:00Z